SB 938, as amended, Jackson. Conservatorships: psychotropic medications.
Existing law authorizes a conservator to place a conservatee in a secured perimeter residential care facility for the elderly, as specified, or to authorize the administration of certain prescribed medications upon a court’s finding that among other things, the conservatee has dementia and a functional impairment. Existing law requires certain findings to be made by the court for each type of authority sought by the conservator and requires a petition for authority to be supported by a declaration of a licensed physician or psychologist, as specified, regarding these findings.
This bill would replace references to the term dementia in these provisions with major neurocognitive disorders (MNCDs), as defined. The bill would require a petition requesting the authority to administer psychotropic medications, as defined, to be supported by a
declaration of a physicianbegin delete or psychologistend delete that includes specified information, including, among other things, the recommended course of medication, the expected effects of the recommended medication on the conservatee’s overall mental health and treatment plan, including how the medication is expected to improve the conservatee’s symptoms, and a description of the potential side effects of the recommended medication. The bill would require the Judicial Council, on or before July 1, 2017, to adopt rules of court and develop appropriate forms for the implementation of these provisions, as specified. The bill would makebegin insert related changes andend insert additional findings and declarations of the Legislature.
Vote: majority. Appropriation: no. Fiscal committee: yes. State-mandated local program: no.
The people of the State of California do enact as follows:
Section 2356.5 of the Probate Code is amended
2to read:
(a) The Legislature hereby finds and declares:
4(1) That conservatees with major neurocognitive disorders
5(MNCDs), as defined in the last published edition of the
6“Diagnostic and Statistical Manual of Mental Disorders,” should
7have a conservatorship to serve their unique and special needs.
8(2) Common forms of MNCDs are known as Alzheimer’s
9disease, vascular dementia, dementia with Lewy bodies, Parkinson
10
dementia, frontotemporal dementia, and mixed dementia.
11(3) That, by adding powers to the probate conservatorship for
12conservatees with MNCDs, their unique and special needs can be
13met, and the basic dignity and rights of the conservatee can be
14safeguarded.
15(4) Psychotropic medications can be misused for people with
16MNCDs to control behavior that conveys pain, distress, or
17discomfort and the administration of psychotropic medications
18has been and can be abused by those who prescribe and administer
19these medications.
20(5) Since 2005, the federal Food and Drug Administration has
21required the packaging of all antipsychotic medications, which
22fall under a class of psychotropic medication, to contain a black
23box
warning label that the medication significantly increases the
24risk of death for elderly people with MNCDs.
P3 1(6) Therefore, granting powers to a conservator to authorize
2these medications for the treatment of a person with an MNCD
3requires thebegin insert additionalend insert protections specified in this section.
4(b) For the purposes of this section, “MNCD” means a major
5neurocognitive disorder, as defined in the latest published edition
6of the “Diagnostic and Statistical Manual of Mental Disorders.”
7(c) Notwithstanding any other law, a conservator may authorize
8the placement of a conservatee in a secured perimeter residential
9care facility for the elderly
operated pursuant to Section 1569.698
10of the Health and Safety Code, and which has a care plan that
11meets the requirements of Section 87705 of Title 22 of the
12California Code of Regulations, upon a court’s finding, by clear
13and convincing evidence, of all of the following:
14(1) The conservatee has an MNCD.
15(2) The conservatee lacks the capacity to give informed consent
16to this placement and has at least one mental function deficit
17pursuant to subdivision (a) of Section 811, and this deficit
18significantly impairs the person’s ability to understand and
19appreciate the consequences of his or her actions pursuant to
20subdivision (b) of Section 811.
21(3) The conservatee needs or would benefit from a restricted
22and secure environment, as demonstrated by evidence presented
23by the physician or psychologist referred to in paragraph (3) of
24subdivision (f).
25(4) The proposed placement in a
secured perimeter residential
26care facility for the elderly is the least restrictive placement
27appropriate to the needs of the conservatee.
28(d) Notwithstanding any other law, a conservator of a person
29may authorize the administration of psychotropic medications to
30a conservatee with anbegin delete MNCD,end deletebegin insert MNCD onlyend insert upon a court’s finding,
31by clear and convincing evidence, of all of the following:
32(1) The conservatee has an MNCD.
33(2) The conservatee lacks the capacity to give informed consent
34to the administration of psychotropic medications for
his or her
35treatment and has at least one mental function deficit pursuant to
36subdivision (a) of Section 811, and this deficit or deficits
37significantly impairs the person’s ability to understand and
38appreciate the consequences of his or her actions pursuant to
39subdivision (b) of Section 811.
P4 1(3) The conservatee needs or would benefit from appropriate
2medication as demonstrated by evidence presented by the physician
3begin delete or psychologist referred to in paragraph (3) ofend deletebegin insert as provided inend insert
4 subdivision (f).
5(e) Pursuant to subdivision (b) of Section 2355, in the case of
6a person who is an adherent of a religion whose
tenets and practices
7call for a reliance on prayer alone for healing, the treatment
8required by the conservator under subdivision (d) shall be by an
9accredited practitioner of that religion in lieu of the administration
10of medications.
11(f) A petition for authority to act under this section is governed
12by Section 2357, except:
13(1) The conservatee shall be represented by an attorney pursuant
14to Chapter 4 (commencing with Section 1470) of Part 1. Upon
15granting or denying authority to a conservator under this section,
16the court shall discharge the attorney or order the continuation of
17the legal representation, consistent with the standard set forth in
18subdivision (a) of Section 1470.
19(2) The conservatee shall be
produced at the hearing, unless
20excused pursuant to Section 1893.
21(3) The petition requesting authority under subdivision (c)begin delete or shall be supported by a declaration of a physician, or a
22(d)end delete
23psychologist within the scope of his or her licensure, regarding
24each of the findings required to be made under this section for any
25powerbegin delete requested, except that the psychologist hasend deletebegin insert requested. The
26psychologist shall haveend insert at least two years of experience in
27diagnosing MNCDs.begin delete The supporting declaration for a petition
28requesting authority under subdivision (d) shall also include all of
29the following:end delete
30
(4) The petition requesting authority under subdivision (d) shall
31be supported by a declaration of a physician regarding each of
32the findings required to be made under this section for any power
33requested. The supporting declaration for a petition requesting
34authority under subdivision (d) shall also include all of the
35following:
36(A) A description of the conservatee’s diagnosis and a
37description of the conservatee’s behavior.
38(B) The recommended course of medication.
39(C) A description of the pharmacological and
40nonpharmacological treatments and medications that have been
P5 1previously used or proposed, the less invasive treatments or
2medications used or proposed, and why these
treatments or
3medications have not been or would not be effective in treating
4the conservatee’s symptoms.
5(D) The expected effects of the recommended medication on
6the conservatee’s overall mental health and treatment plan,
7including how the medication is expected to improve the
8conservatee’s symptoms.
9(E) A description of the potential side effects of the
10
recommended medication, including any black box warnings issued
11by the federal Food and Drug Administration as defined in Section
12201.57(c)(1) of Title 21 of the Code of Federal Regulations.
13(F) Whether the conservatee and his or her attorney have had
14an opportunity to provide input on the recommended medications.
15(4)
end delete
16begin insert(5)end insert On or before July 1, 2017, the Judicial Council shall adopt
17rules of court and develop appropriate forms for the implementation
18of this section, and shall provide guidance to the court on how to
19evaluate
the request for authorization, including how to proceed
20if information, otherwise required to be included in a request for
21authorization under this section, is not included in a request for
22authorization submitted to the court.
23(5)
end delete
24begin insert(6)end insert The petition may be filed by any of the persons designated
25in Section 1891.
26(g) The court investigator shall annually investigate and report
27to the court every two years pursuant to Sections 1850 and 1851
28if the conservator is authorized to act under this section. In addition
29to the other matters
provided in Section 1851, the conservatee shall
30be specifically advised by the investigator that the conservatee has
31the right to object to the conservator’s powers granted under this
32section, and the report shall also include whether powers granted
33under this section are warranted. If the conservatee objects to the
34conservator’s powers granted under this section, or the investigator
35determines that some change in the powers granted under this
36section is warranted, the court shall provide a copy of the report
37to the attorney of record for the conservatee. If no attorney has
38been appointed for the conservatee, one shall be appointed pursuant
39to Chapter 4 (commencing with Section 1470) of Part 1. The
P6 1attorney shall, within 30 days after receiving this report, do one
2of the following:
3(1) File a petition with the court regarding the status of the
4conservatee.
5(2) File a written report with the court stating that the attorney
6has met with the conservatee and determined that the petition
7would be inappropriate.
8
(h) If authority to administer psychotropic medications is
9granted pursuant to subdivision (d), the conservator may change
10or adjust psychotropic medications without further notice to, or
11approval from, the court, provided that the change or adjustment
12is consistent with the authority granted by the court and the
13conservator has received information about the risks, benefits,
14and alternatives of the proposed change or adjustment in advance
15of approving the change or adjustment.
16
(i) If the
authority to administer psychotropic medications is
17granted pursuant to subdivision (d), the court shall review the
18grant of authority as part of its periodic review conducted pursuant
19to Section 1850.
20(h)
end delete
21begin insert(j)end insert A petition to terminate authority granted under this section
22shall be governed by Section 2359.
23(i)
end delete
24begin insert(k)end insert Nothing in this section shall be construed to affect a
25conservatorship of the estate of a person who has an MNCD.
26(j)
end delete
27begin insert(l)end insert Nothing in this section shall affect the laws that would
28otherwise apply in emergency situations.
29(k)
end delete
30begin insert(m)end insert Nothing in this section shall affect current law
regarding
31the power of a probate court to fix the residence of a conservatee
32or to authorize medical treatment for any conservatee who has not
33been determined to have an MNCD.
34(l)
end delete
35begin insert(n)end insert For purposes of this section, “psychotropic medications”
36includes, but is not limited to, anxiolytic agents, antidepressants,
37mood stabilizers, antipsychotic medications,begin delete anti-Parkinsonend delete
agents,
38hypnotics, and psychostimulants. “Psychotropic medications” does
39not include medications approved by the federal Food and Drug
P7 1Administration for the treatment of anbegin delete MNCD.end deletebegin insert
MNCD or
2anti-Parkinson agents.end insert
3
(o) This section shall not apply to a conservatee who is
4prescribed a psychotropic or antipsychotic medication by a
5physician in an acute care hospital setting or for purposes of
6diagnosis or therapeutic treatment not directly related to the
7MNCD, including, but not limited to, sedation prior to an invasive
8procedure or nausea prevention or relief. In those circumstances,
9the informed consent of the conservator may be obtained pursuant
10to the authority granted under Section 2355.
O
96